Skip to main content
Triangle logo TriangleGet started

Orca-T (NCT07216443)

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: a one-minute explainerNCT072164431 min

Orca-T trial for Leukemia, Myeloid, Acute (NCT07216443). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with acute myeloid or mixed-phenotype leukemia in remission, or qualifying myelodysplastic syndrome. Patients need a matched donor and must be unsuitable for high-intensity transplant conditioning.

The idea: Orca-T combines donor stem cells with purified regulatory and conventional T cells. After lower-intensity chemotherapy and total-body radiation, patients receive Orca-T and tacrolimus to prevent graft-versus-host disease. Researchers assess transplant safety, blood-cell recovery, and survival without relapse or graft-versus-host disease. Prior donor transplantation is excluded.

This phase 2 study plans 80 patients. Orca Biosystems sponsors; six US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.